摘要:
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
摘要:
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
摘要:
Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.
摘要:
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
摘要:
Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
摘要:
The present invention provides piperazine derivatives and methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders.
摘要:
Disclosed are sultam compounds of Formula (I) or a pharmaceutically-acceptable salt thereof. Also disclosed are methods of using such compounds in the treatment of at least one nuclear hormone receptor-associated condition, such as, for example, cancer and immune disorders, and at least one pharmaceutical composition comprising such compounds.
摘要:
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
摘要:
The present invention is directed to compounds having the formula (I), and/or pharmaceutically-acceptable salts thereof, useful in the treatment of androgen-receptor associated conditions, wherein Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; L is a linker as defined in the specification; R1 may be hydrogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclo, substituted heterocyclo, heteroaryl, or substituted heteroaryl, as defined in the specification; R2 is hydrogen, lower alkyl, or substituted lower alkyl; and R3, R4 and R5 are optionally non-interfering substituents as defined in the specification.
摘要翻译:本发明涉及可用于治疗雄激素受体相关病症的式(I)化合物和/或其药学上可接受的盐,其中Ar为芳基,取代的芳基,杂芳基或取代的杂芳基; L是说明书中定义的接头; R 1可以是如本说明书中定义的氢,氰基,烷基,取代的烷基,芳基,取代的芳基,环烷基,取代的环烷基,杂环,取代的杂环,杂芳基或取代的杂芳基; R 2是氢,低级烷基或取代的低级烷基; 并且R 3,R 4和R 5可以是说明书中定义的任选的非干扰性取代基。